SCHEMBL3529231

SCHEMBL3529231

CN1CCC(N(C)c2ccc(C(=O)O)cc2C(F)(F)F)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.42
NOS1 P29475 1/20 0.42
NOS2 P35228 1/20 0.42
MCHR1 Q99705 2/20 0.40
LMNA P02545 3/20 0.39
TTR P02766 2/20 0.39
KDM4E B2RXH2 2/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ERAP1 Q9NZ08 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
SLC6A5 Q9Y345 1/20 0.39
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
KDM2B Q8NHM5 1/20 0.38
P2RY14 Q15391 1/20 0.38
PTK2 Q05397 1/20 0.38
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5929406 0.84 NOS3 (0.40) NOS3NOS1NOS2MCHR1TTR
SCHEMBL1408291 0.79 NR1H2 (0.49) NOS3NOS1NOS2HTR2AHTR2C
SCHEMBL27195840 0.78 SLC9A1 (0.55) HTR2A
SCHEMBL1407806 0.77 ALDH1A1 (0.47) NOS3NOS1NOS2LMNAMAPT
SCHEMBL16269107 0.75 SMO (0.52) PDE3BPDE3A
SCHEMBL3557511 0.75 DDR1 (0.56) NOS3NOS1NOS2LMNATTR
SCHEMBL2313914 0.75 KDM4E (0.55) LMNATTRKDM4EMAPTNPSR1
SCHEMBL28586091 0.72 POLQ (0.43) TTRSRD5A2
SCHEMBL3533360 0.72 TTR (0.59) TTRKDM4EERAP1PDE3BPDE3A
SCHEMBL20951950 0.72 KDM2B (0.53) LMNAHTR2AHTR2CKDM2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655669-B2 Pyrimidineamide derivatives and the use thereof NOVARTIS AG (CH) 2010-02-02 US disclosed
CN-100404528-C Novel pyrimidinamine derivatives and use thereof NOVARTIS AG (CH) 2008-07-23 CN disclosed
EP-1546127-B1 NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF NOVARTIS AG (CH) 2007-08-08 EP disclosed
US-20060142577-A1 Novel pyrimidineamide derivatives and the use thereof NOVARTIS AG (CH) 2006-06-29 US disclosed
CN-1684951-A Novel pyrimidinamine derivatives and use thereof NOVARTIS AG (CH) 2005-10-19 CN disclosed
EP-1546127-A1 NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF Novartis AG (CH) 2005-06-29 EP disclosed
WO-2004029038-A1 NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF NOVARTIS AG (CH) 2004-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142577-A1 Novel pyrimidineamide derivatives and the use thereof TYMP, NME2, DPYD NOS3 3614/4885NOS1 4025/4885NOS2 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.